Journal article
Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk
WR Leifert, T Nguyen, A Rembach, R Martins, S Rainey-Smith, CL Masters, D Ames, CC Rowe, SL Macaulay, M François, MF Fenech
Journal of Alzheimer S Disease | IOS PRESS | Published : 2015
DOI: 10.3233/JAD-150330
Abstract
Mild cognitive impairment (MCI) may reflect early stages of neurodegenerative disorders such as Alzheimer's disease (AD). Our hypothesis was that cytokeratin 14 (CK14) expression could be used with blood-based biomarkers such as homocysteine, vitamin B12, and folate to identify individuals with MCI or AD from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging. Buccal cells from 54 individuals were analyzed by a newly developed method that is rapid, automated, and quantitative for buccal cell CK14 expression levels. CK14 was negatively correlated with plasma Mg2+ and LDL, while positively correlated with vitamin B12, red cell hematocrit/volume, and basophils in th..
View full abstractGrants
Funding Acknowledgements
We thank Mr. Bryan Yuen (Metasystems Asia) for providing helpful advice on establishing the Metafer software protocol. We thank Jannatul Ferdoush Tuli, Maryam Hor, Theodora Almond, and Candita Dang for assisting with the preparation of microscope slides, and Drs. Sam Burnham, Mary Barnes, and James Doecke for statistical advice. We thank all the participants who took part in this study and the clinicians who referred participants. The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) study is a collaboration between CSIRO Australia, Edith Cowan University (Perth, Western Australia, Australia), The Florey Institute of Neuroscience and Mental Health (Melbourne, Victoria, Australia), National Ageing Research Institute and Austin Health (Parkville, Victoria, Australia). It also involves support from CogState Ltd. (Melbourne, Victoria, Australia), Hollywood Private Hospital and Sir Charles Gairdner Hospital (Nedlands, Western Australia, Australia). The AIBL study received funding support from the Science and Industry Endowment Fund, National Health and Medical Research Council (NHMRC) and Dementia Collaborative Research Centres (DCRC), Alzheimer's Australia and the McCusker Alzheimer's Research Foundation, as well as Industry, including Pfizer, Merck, Janssen and GE Healthcare. Financial support from the CSIRO's Preventative Health Flagship is gratefully acknowledged. WRL received a grant from The JO&JR Wicking Trust, which is managed by ANZ Trustees (Australia). The authors thank all the AIBL investigators (https://aibl.csiro.au/).